Condition (MeSH)
Communicable Diseases, Emerging
ClinicalTrials.gov lists 16 trials for Communicable Diseases, Emerging or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Communicable Diseases, Emerging itself; the rest are tagged with a narrower condition beneath it.
When did Communicable Diseases, Emerging trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 3 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2015 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Communicable Diseases, Emerging trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Not applicable | 2 |
| Observational | 10 |
How many Communicable Diseases, Emerging trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Completed | 5 |
| Suspended | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Communicable Diseases, Emerging trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Arisan Therapeutics, Inc. | 1 |
| Chisquares Incorporated | 1 |
Which drugs are being tested for Communicable Diseases, Emerging? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| AVIGAN | 1 |
| Fresh Frozen Plasma | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ribavirine | 2 |
| Standard Care | 1 |
| Baritinib | 1 |
| ARN-75039 high dose | 1 |
| Dexamethasone/Dexamethasone acetate | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Communicable Diseases, Emerging trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute respiratory distress syndrome | 3 | 1 |
| Cerebrovascular accident | 3 | 1 |
| Endotracheal intubation | 2 | 1 |
| Hyperkalaemia | 2 | 1 |
| Intestinal ischaemia | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Communicable Diseases, Emerging? (98)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Mitigating the Impact of Emerging Animal Infectious Disease Threats: First Emerging Animal Infectious Diseases Conference (EAIDC) Report. | Viruses | 2022 | Yes |
| Role of Ophthalmology in Emerging Infectious Diseases. | JAMA ophthalmology | 2022 | Yes |
| Vaccine development for emerging infectious diseases. | Nature medicine | 2021 | Yes |
| A new coronavirus associated with human respiratory disease in China. | Nature | 2020 | Yes |
| Emerging coronaviruses: Genome structure, replication, and pathogenesis. | Journal of medical virology | 2020 | Yes |
Showing 5 of 98 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.